This site is intended for healthcare professionals

FDA expands approval of Kyprolis to include combination with Darzalex Faspro and dexamethasone.

Read time: 1 mins
Last updated:20th Dec 2021
Published:2nd Dec 2021
Amgen announced that the FDA has approved the expansion of the Kyprolis (carfilzomib) U.S. prescribing information to include its use in combination with Darzalex Faspro (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

The expansion of the Kyprolis prescribing information to include Darzalex Faspro plus dexamethasone was supported by the ongoing, Phase 2, non-randomized, open-label, multicenter PLEIADES trial evaluating the clinical benefit of Darzalex Faspro administered in combination with four standard-of-care treatment regimens in patients with multiple myeloma.

Updated data from the PLEIADES study were presented at the 2020 American Society of Hematology (ASH) Annual Meeting, demonstrating that response rates with Kyprolis in combination with Darzalex Faspro and dexamethasone were similar to those in the Phase III CANDOR study (Kyprolis combined with intravenous [IV] Darzalex and dexamethasone [DKd]), which supported the first-ever approval of an anti-CD38 monoclonal antibody in combination with Kyprolis. The PLEIADES study met its primary endpoint, demonstrating an overall response rate of 84.8 percent with Darzalex Faspro-Kd.

Condition: Multiple Myeloma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.